These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33159275)

  • 21. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
    Mata JR; Zahurak M; Rosen N; DeZern AE; Jones RJ; Ambinder AJ
    Transplant Cell Ther; 2024 Jun; 30(6):588-596. PubMed ID: 38521411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
    Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
    Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-Transplant CD34
    Chandra S; Bleesing JJ; Jordan MB; Grimley MS; Khandelwal P; Davies SM; Edwards S; Leemhuis T; Marsh RA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1527-1529. PubMed ID: 29555312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.
    Jacoby E; Chen A; Loeb DM; Gamper CJ; Zambidis E; Llosa NJ; Huo J; Cooke KR; Jones R; Fuchs E; Luznik L; Symons HJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):112-8. PubMed ID: 26343947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol.
    Raiola AM; Angelucci E; Sica S; Bacigalupo A
    Blood Rev; 2023 Nov; 62():101031. PubMed ID: 36435691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
    Prata PH; Resche-Rigon M; Blaise D; Socié G; Rohrlich PS; Milpied N; Turlure P; Nguyen S; Sirvent A; Bulabois CE; Berceanu A; Charbonnier A; Chevallier P; Bay JO; Neven B; Jubert C; Mohty M; Rubio MT; Peffault de Latour R
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1798-1802. PubMed ID: 31129355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders.
    Klein OR; Chen AR; Gamper C; Loeb D; Zambidis E; Llosa N; Huo J; Dezern AE; Steppan D; Robey N; Holuba MJ; Cooke KR; Symons HJ
    Biol Blood Marrow Transplant; 2016 May; 22(5):895-901. PubMed ID: 26860634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts.
    Lu Y; Xiong M; Sun RJ; Zhao YL; Zhang JP; Cao XY; Liu DY; Wei ZJ; Zhou JR; Lu DP
    Hematology; 2021 Dec; 26(1):134-143. PubMed ID: 33491597
    [No Abstract]   [Full Text] [Related]  

  • 35. Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.
    Durand CM; Capoferri AA; Redd AD; Zahurak M; Rosenbloom DIS; Cash A; Avery RK; Bolaños-Meade J; Bollard CM; Bullen CK; Flexner C; Fuchs EJ; Gallant J; Gladstone DE; Gocke CD; Jones RJ; Kasamon YL; Lai J; Levis M; Luznik L; Marr KA; McHugh HL; Mehta Steinke S; Pham P; Pohlmeyer C; Pratz K; Shoham S; Wagner-Johnston N; Xu D; Siliciano JD; Quinn TC; Siliciano RF; Ambinder RF
    Lancet HIV; 2020 Sep; 7(9):e602-e610. PubMed ID: 32649866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations.
    Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bykova TA; Chukhlovin AB; Pevtcov DE; Bondarenko SN; Afanasyev BV
    Eur J Haematol; 2018 May; 100(5):395-402. PubMed ID: 29360184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children.
    Neven B; Diana JS; Castelle M; Magnani A; Rosain J; Touzot F; Moreira B; Fremond ML; Briand C; Bendavid M; Levy R; Morelle G; Vincent M; Magrin E; Bourget P; Chatenoud L; Picard C; Fischer A; Moshous D; Blanche S
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1363-1373. PubMed ID: 30876929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.